Hck and Lyn are required in Philadelphia chromosome (Ph) positive acute lymphocytic leukemia (ALL). Here, we present evidence that the promoter CpG island of Hck, but not of Lyn, is aberrantly methylated in leukemia. Hck promoter DNA methylation was detected in 13 out of 23 (56.5%) hematopoietic and eight out of 10 (80%) non-hematopoietic cell lines, but not in normal controls. Treatment with 5-aza-2 0 -deoxycytidine induced demethylation and restoration of Hck mRNA and protein expression. Hck methylation (X15%) was detected in nine out of 44 (20%) patients with Ph negative ALL, and in one out 16 (6%) patients with Ph positive ALL, but not in patients with AML or chronic myelogenous leukemia. In this subset of patients, low levels of Hck methylation (10-15%) were observed in 26-30% of patients. Lyn methylation was observed in three out of 28 (10.7%) cell lines, but only in one out of 71 (1.4%) patients. Patients with Ph negative ALL and Hck methylation had a poorer prognosis. These data indicate that Hck may have tumor suppressor properties in BCR-ABL negative leukemia. Leukemia (2007) 21, 906-911.
Introduction
Philadelphia chromosome (Ph) positive leukemias are characterized by the presence of the BCR-ABL oncogene. 1 Bcr-Ablinduced Src kinase signaling is important in chronic myelogenous leukemia (CML). [2] [3] [4] Src kinases form a family of nine structurally homologous non-receptor intracellular tyrosine kinases that regulate signal transduction pathways involved in cell growth, differentiation and survival. 5 Src kinases are expressed in a tissue-specific manner and five of them, Hck, Lyn, Fgr, Lck and Blk, are strictly restricted to hematopoietic cells. Specifically, Hck expression is circumscribed to myeloid cells and B lymphocytes, whereas Lyn is expressed in myeloid cells, B lymphocytes and NK cells. 5 In myeloid cell lines, BcrAbl activates both Lyn and Hck kinases. 2, [6] [7] [8] In CML, overexpression and/or activation of Hck and Lyn are associated with disease progression. 4 It has been reported that bone marrow cells from mice lacking Hck, Lyn and Fgr, retrovirally transduced with BCR-ABL1, efficiently induced CML but not B-cell acute lymphocytic leukemia (ALL) in recipient mice. It was also demonstrated that the Src kinase inhibitor CGP76030 abrogated in vitro proliferation of lymphoid B-cells expressing Bcr-Abl and prolonged survival of mice with B-cell ALL but not CML. 9 These data indicate that expression of Hck and Lyn is crucial for B-cell ALL induction by Bcr-Abl but not for CML. 9 In contrast with the oncogenic potential of Hck and Lyn just described, their function in Ph negative leukemia is not currently understood. It has been reported that Hck can promote kinasedependent caspase-mediated apoptosis. 10 This suggests that Hck may have tumor suppressor properties outside the context of Bcr-Abl positive leukemias.
At the present time, little is known regarding the mechanisms of regulation of Hck and Lyn gene expression. Both genes contain a CpG island in the proximity of their promoters. Therefore, it is possible that Hck and Lyn expression is modulated by epigenetic modifications such as DNA methylation. To study the prevalence and clinical and biologic implications of Hck and Lyn methylation in leukemia, we have performed the studies shown here.
Materials and methods
Cell lines, human samples and treatment with 5-aza-2 0 -deoxycytidine Analysis of cell viability. Cell viability of 5-aza-2 0 -deoxycitidie-treated cells was performed as described previously.
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In summary, cell viability was assessed using trypan blue staining (Sigma, St Louis, MO, USA). After culture, cells were harvested and stained with 0.4% trypan blue solution. Stained cells were counted immediately using conventional microscopy.
Extraction of DNA and RNA DNA was extracted following standard phenol-chloroform procedures. RNA was extracted using Trizol (Invitrogen, Calisbad, CA, USA) following the manufacturer's recommendations.
Bisulfite treatment and combined bisulfite restriction analysis (COBRA) This was performed as described previously. 12, 13 Detailed information, including primer sequences, is shown in Supplementary Information.
Bisulfite sequence analysis
PCR products amplified with primers Hck-BS4 and Hck-BS5 (Supplementary Table 1 ) were cloned into pCR4-TOPO vector using a TOPO-cloning kit (Invitrogen) and directly sequenced in a core sequencing facility at the University of Texas MD Anderson Cancer Center. 12 
Real-time PCR
Real-time PCR was performed as described previously 
Protein extraction and Western immunobloting
This was performed as described previously 11 following standard procedures (Supplemental Information).
Statistical analysis
Overall survival (OS) was measured from the first day of therapy to the date of death or the date of the last follow-up in all assessable patients. Disease-free survival (DFS) for patients who had achieved complete remission (CR) was measured from the date of documentation of CR to the date of relapse or death. OS and DFS were determined according to the Kaplan-Meier method. For survival analysis, a sample was considered methylated if the ratio of methylated to unmethylated PCR product was X10%.
Results

Hck promoter-associated CpG island is methylated in cancer cell lines but not in normal controls
The DNA methylation status of the promoter region of Hck in hematopoietic and non-hematopoietic cell lines, as well as in samples from normal controls, was studied using the combined bisulfite restriction assay (COBRA).
13,14 Figure 1 shows representative examples. Overall, 23 hematopoietic (nine CML, seven ALL and seven AML) cell lines (Table 1) , 10 nonhematopoietic (three colon, three prostate, two breast and two liver) cell lines (Supplementary Table 2 ) and five normal healthy individuals (Table 1) were analyzed. Hck was methylated (X15%) in five of nine CML-derived (WDT2 50%, WDT3 24%, K562R 26%, BV173 64%, BV173R 50%), two of seven AML-derived (NB4 57%, OCI-AML 32%), five of five T-cell ALLderived (CEM 88%, Molt-4 15%, Jurkat 18%, T-ALL1 70%, PEER 47%) and one of two B-cell ALL-derived (Raji 92%) hematopoietic cell lines. In contrast, Hck methylation was absent in bone marrow cells from normal controls. Hck promoter DNA methylation was observed in K562R cells (26%) that are imatinib resistant, but not in the original K562 cell line. HcK protein and mRNA expression was inversely correlated with the level of DNA methylation as evidenced by Western blot analysis in cell lines (Figure 2 ), and real-time PCR assays (Table1 and Figure 3 ). Hck methylation in leukemia K Hocino et al
In non-hematopoietic cell lines, Hck was found methylated in three of three colon cancer-derived (RKO 83%, HCT116 87%, SW48 40%), one of two breast cancer-derived (MB435 34%), two of two liver cancer-derived (HEPG2 10%, HEP3B 14%) and two of three prostate cancer-derived (DU145 33%, LNCAP 0%, U373 17%) cell lines (Supplementary Information).
Hck expression can be restored by 5-aza-2 0 -deoxycytidine To investigate the relationship between aberrant DNA methylation of the Hck promoter and Hck expression, we treated five cell lines (K562, K562R, BV173, NB4 and Raji) with 1 mM of the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine daily for 3 days. Treatment with 5-aza-2 0 -deoxycytidine resulted in significant decrease in methylation density and increased Hck gene expression in three of four cell lines with significant Hck promoter methylation (K562R, BV173 and Raji) ( Table 2) . Complete Hck demethylation was observed in K562R after 5-aza-2 0 -deoxycytidine treatment (26-0%) ( Table 2 ). In Raji, the expression of Hck mRNA increased after treatment with 5-aza-2 0 -deoxycytidine approximately 2 000-fold compared with the untreated cell line and the density of Hck methylation decreased from 92 to 39% (Figure 3 ). These last results were confirmed by bisulfite DNA sequencing (Figure 3 ). Significant reductions in Hck methylation were also observed in BV173 (64-14%), but not in NB4 (57-48%). To study the effects of 5-aza-2 0 -deoxycytidine on Hck protein expression, we performed Western blot analysis: Hck protein expression was remarkably increased in Raji cells after treatment with 5-aza-2 0 -deoxycytidine (Figure 2 ), in accordance with the increase in Hck mRNA expression. In aggregate, these results strongly suggest that aberrant DNA methylation of the Hck promoter results in gene silencing, and that this phenomenon can be reversed using a hypomethylating agent. In parallel with Hck reactivation, treatment with 5-aza-2 0 -deoxycitidine was also associated with a significant decrease in cell viability both in Raji and NB4 cells (Supplementary Figure 3) .
Aberrant promoter DNA methylation of Hck in human leukemia
After these initial results in leukemia cell lines, we studied the frequency of Hck methylation in patients with leukemia. Representative examples of Hck methylation are shown in Figure 4 . The distribution of Hck DNA methylation is shown in Table 3 . Dense (X15%) Hck methylation levels were observed in nine out of 44 (20%) patients with Ph negative ALL, but only in one of 16 (6%) patients with Ph positive ALL. Of note, except for one patient with Ph positive ALL, Hck methylation 415% was detected only in patients with Ph negative ALL. A level of Hck methylation between 11 and 15% was found in six of 23 (26%) patients with CML and three of 10 (30%) patients with AML (Table 3 and Supplementary Figure 2) . The clinical characteristics of the patients with ALL are summarized in Supplementary Table 3 . Methylation results were confirmed by bisulfite sequencing (data not shown). Finally, we analyzed the levels of Hck methylation in patients with ALL at the time of remission. Hck methylation was detected in three out of 21 (14%) patients with Ph negative ALL at remission (data not shown).
Hck is silenced in a subset of patients with ALL
In cell lines, HcK methylation was strongly associated with gene silencing. Therefore, we studied the level of Hck mRNA expression in a subset of patients with Ph negative ALL from whom cDNA was available. Hck gene expression was not detected in four out of 12 (33%) patients with Ph-ALL, all of which had Hck methylation (data not shown).
Lyn promoter DNA methylation is a rare event in leukemia
The frequency of DNA methylation of the Lyn promoter CpG island was also studied. Lyn promoter methylation was not detected in any of the normal controls, but in three of 28 (11%) cell lines (19 hematopoietic and nine non-hematopoietic) analyzed. All Lyn methylated cell lines were of T-cell lineage (CEM, T-ALL1 and Jurkat) (Figure 1b) . In contrast, Lyn promoter methylation was observed in only one patient with Ph negative ALL of 71 (1.4%) leukemia patients (31 ALL, 27 CML and 13 AML) studied (data not shown).
Correlation between Hck promoter methylation and clinical outcome in ALL
Using the Kaplan-Meier method, we explored the clinical impact of Hck methylation in patients with Ph negative ALL. We observed a trend toward improved OS (P ¼ 0.089) and DFS (P ¼ 0.139) in the subset of patients with Ph negative ALL and no Hck methylation compared with patients with Ph negative ALL and Hck methylation at the time of diagnosis ( Figure 5 ).
Discussion
DNA methylation of promoter-associated CpG islands is an epigenetic modification described in virtually every type of human malignancy. [15] [16] [17] This molecular alteration is very frequent in leukemia, and it is particularly prevalent in ALL. 12, [18] [19] [20] [21] [22] [23] [24] [25] [26] In this study, we present evidence that aberrant DNA methylation of the Hck promoter is common in malignant cell lines but not in bone marrow cells from normal controls. Hck methylation was associated with decreased Hck mRNA and protein expression. Treatment with the hypomethylating agent 5-aza-2 0 -deoxycytidine was associated with Hck DNA hypomethylation, increase mRNA, and protein expression. These indicate that aberrant DNA methylation of the Hck promoter is associated with its silencing.
Hck promoter methylation was not restricted to cell lines. Dense Hck promoter methylation (X15%) was observed in 20% of patients with Ph negative ALL (34% if a cutoff of 10% for methylation was used). This phenomenon was specific for patients with Ph negative ALL, as a level of more than 15% methylation of Hck was observed only in one out of 16 (6%) patients with Ph positive ALL, and in none of the patients with AML or CML studied. In patients with CML and AML low levels of Hck DNA methylation were observed. Low levels of gene specific methylation are frequently observed in cancer and are Hck methylation in leukemia K Hocino et al thought to be of no biological significance. 21 There was discordance between the frequency of Hck methylation in CML-derived cell lines and its frequency in human patient samples. This discordance can be explained in part as owing to in vitro acquisition of aberrant DNA methylation related to extensive cell passage and aging of cancer cell lines not representative of physiological conditions. Further supporting the notion that epigenetic regulation may have a role in the control of Hck expression in vivo, we could not detect Hck mRNA expression in 33% of the patients studied with Ph negative ALL. Hck methylation was associated with a trend toward a worse prognosis in patients with Ph negative ALL. If confirmed by further studies, this phenomenon is of importance as it will question the targeting of Src signaling in Ph negative ALL. Residual Hck methylation could be detected in a subset of patients with Ph negative ALL at the time of morphological remission.
Aberrant DNA methylation was restricted to Hck, as only 1% of the patient samples analyzed had Lyn promoter DNA methylation. Of interest, Lyn promoter DNA methylation was restricted to leukemia cell lines of T-cell ALL origin. Therefore, more extensive studies of Lyn methylation in T-cell ALL are needed.
There are several important implications from the data presented here. The fact that Hck can undergo aberrant DNA methylation in Ph negative ALL indicates that in this context Hck may have potential tumor suppressor properties. This is further supported by evidence presented here that treatment with low doses of a hypomethylating agent that induce Hck demethylation/reactivation are associated with decreased cell viability. This is in discordance with the known oncogenic potential of Hck in Ph positive leukemias, 9 and suggests that the function of Hck may be conditioned by its cellular/molecular context. The association between Hck methylation and a trend toward worse prognosis supports this concept. This phenomenon cannot be explained at the present time with current evidence. It is possible that Hck signaling is associated with downstream effects that are tumor suppressive instead of oncogenic in Ph negative ALL. In fact, evidence indicating that Hck may have proapoptotic function 10 suggests that loss of Hck-mediated apoptotic may potentially play a role in Ph negative ALL. As evidenced by our in vitro studies, aberrant Hck methylation can be reversed by exposing cells to a hypomethylating agent. This clinical implications as suggests that 5-aza-2 0 -deoxycitidine may have clinical activity in ALL.
Another important observation from this study relates to the fact that K562R cells that are imatinib resistant, but not K562, have Hck methylation. So it is possible that Hck methylation may be involved in imatinib resistance in these cells and in CML patients. Indeed, 5-aza-2 0 -deoxycitidine has been shown to have clinical activity in imatinib resitant CML. 27 The role of Hck inactivation in imatinib resistance therefore needs further studies.
The main limitation of the data presented is that we had not demonstrated direct evidence that Hck reactivation, and its potential tumor suppressor properties, have an active role in the induction of cell death and show a trend toward worse prognosis in Ph negative ALL. This needs to be studied at the cellular level using inducible cell transfection systems.
In summary, in this study we have documented that the promoter of the Src kinase Hck can undergo aberrant DNA methylation in leukemia cells and in patients with Ph negative ALL. Aberrant Hck methylation is associated with epigenetic silencing of both Hck mRNA and protein expression. This can be reversed by exposing cells to a DNA hypomethylating agent that is associated with a decrease in cell viability. Hck methylation was associated with a trend toward a worse outcome in patients with Ph negative ALL, further supporting Hck as a potential tumor suppressor gene in Ph negative ALL. Further studies are needed to elucidate the potential role of Hck as a tumor suppressor gene in Ph negative ALL.
